Search

Search Constraints

You searched for: Author/Creator Yarasheski, Kevin E.

Search Results

1. An examination of baseline plasma Aβ42/40 and intra‐individual cognitive variability (IICV) associations with longitudinal cognitive change in a Black Cohort: Data from the African Americans Fighting Alzheimer's in Midlife (AA‐FAIM) study. (20th December 2022)

2. Comparison of C2N Diagnostics' Aβ40, 42, and 42/40 ratio in Plasma Stored in Micronic and Sarstedt Tubes. (20th December 2022)

3. Diabetes is related to cognition but not plasma amyloid‐β 42/40 in an African American cohort. (20th December 2022)

5. Effect of Race on Prediction of Brain Amyloidosis by Plasma Aβ42/Aβ40, Phosphorylated Tau, and Neurofilament Light. (19th July 2022)

6. F4‐01‐01: PLASMA TEST FOR AMYLOID RISK SCREENING: THE C2N SPONSORED PARIS ADD‐ON STUDY TO IDEAS. (1st July 2019)

8. Pilot Study of Pioglitazone and Exercise Training Effects on Basal Myocardial Substrate Metabolism and Left Ventricular Function in HIV-Positive Individuals with Metabolic Complications. Issue 6 (November 2013)

9. Plasma amyloid‐beta42/40 ratio as biomarker of cerebral amyloidosis in cognitively unimpaired APOE‐e4 homozygotes, heterozygotes and non‐carriers: Biomarkers (non‐neuroimaging) / plasma/serum/urine biomarkers. (7th December 2020)

10. Plasma Aβ42/40 and PET amyloid associations among late‐middle‐aged African Americans: Preliminary results from the AA‐FAIM study. (20th December 2022)